Nemaura Medical Inc

Chart & Performance

D1W1MN

P/E

—

P/S

0.05

EPS

—

Div Yield, %

—

Shrs. gr., 5y

-30.19%

Rev. gr., 5y

Revenues

77k

-84.71%

Net income

-14m

L+1.85%

CFO

-8m

L+29.95%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Nemaura Medical Inc. is a medical technology company dedicated to inventing, developing, and bringing to market diagnostic medical devices. Its flagship product, sugarBEAT, is an innovative, non-invasive continuous glucose monitoring (CGM) system. This device is designed to assist individuals with Type 1 and Type 2 diabetes in managing their condition, and it can also screen for pre-diabetic states. Beyond this, Nemaura offers proBEAT, a wellness guidance service that delivers educational prompts to users about factors influencing their blood sugar profiles. The company also conducts specialized programs aimed at diabetes prevention and reversal. Established in 2009, Nemaura Medical Inc. operates from its headquarters in New York City.

URL

https://nemauramedical.com/

IPO date

Nov 04, 2014

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑03	2022‑03	2021‑03	2020‑03	2019‑03	2018‑03	2017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT